Concepedia

Harit Parakandi

HP

Statistics

Publications

4

Citations

1.9K

H-Index

4

Active since

2012

Affiliations

University of Pennsylvania(Current)

Novartis (United States)

Philadelphia University

Parker Institute for Cancer Immunotherapy

Harit Parakandi is an author at University of Pennsylvania specializing in cancer immunotherapy, chimeric antigen receptor t-cell therapy, and cancer immunology.

Publications per year

2012–2021

4

Publications

4

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.8K citations · Full text

, , +16

Beneficial Regulation of Fibrillar Collagens, Heat Shock Protein-47, Elastin Fiber Components, Transforming Growth Factor-β1, Vascular Endothelial Growth Factor and Oxidative Stress Effects by Copper in Dermal Fibroblasts

Neena Philips, Samuel Philips, Harit Parakandi et al. · Connective Tissue Research · 2012 · 42 citations

, , +15

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2021 · 25 citations · Full text

, , +16

Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy

Elise A. Chong, J. Joseph Melenhorst, Jakub Svoboda et al. · Blood · 2017 · 22 citations

, , +9

1–4 of 4